DiscoverPharma Market Access Insights - from Mtech AccessArtificial intelligence (AI) in clinical trials: Implications for evidence synthesis and market access
Artificial intelligence (AI) in clinical trials: Implications for evidence synthesis and market access

Artificial intelligence (AI) in clinical trials: Implications for evidence synthesis and market access

Update: 2023-10-26
Share

Description

How is Artificial Intelligence being used in the development of new medicines? What role can AI currently play in clinical trials? Where can AI bridge gaps and solve challenges? What could this mean for the future of market access?

In this webinar, Dr George Magrath explains how his team at Lexitas are using AI in clinical trials in the field of ophthalmology. George and Calum explore:

- How, when and where AI is being used in clinical trials
- How Lexitas are using AI in clinical trials for ophthalmology
- Where AI may offer solutions to existing obstacles in clinical trials and ophthalmic drug development
- What the future holds for AI in the development of new medicines
- The role AI can play in selecting patients for clinical trials
- The impact AI may have on the way we evaluate drug effectiveness
- What this all means for evidence synthesis, health economics, reimbursement and market access
- The future prospects of AI in pharmaceutical development

Learn more at: https://mtechaccess.co.uk/ai-clinical-trials-evidence/

This episode was first broadcast as a live webinar in August 2023. 

Subscribe to our newsletter to hear more news, insights and events from Mtech Access.

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Artificial intelligence (AI) in clinical trials: Implications for evidence synthesis and market access

Artificial intelligence (AI) in clinical trials: Implications for evidence synthesis and market access

Mtech Access